Radiotherapy in late elderly (aged 75 or older) patients with paranasal simus carcinoma : a single institution experience．
Radiotherapy in late elderly (aged 75 or older) patients with paranasal simus carcinoma : a single institution experience．
复制标题
晚期老年（75 岁或以上）鼻旁鼻癌患者的放射治疗：单一机构的经验。
DOI：
10.1007/s00405-016-4151-x
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Doi H，Kitajima K，Tanooka M，Terada T，Noguchi K，Takada Y，Fujiwara M，Ishikura R，Kamikonya N，Hirota S．
中科院分区：
文献类型：
--
作者：
Kosaka K;Tanooka M;Doi H;Inoue H;Tarutani K;Suzuki H;Takada Y;Fujiwara M;Kamikonya N;Hirota S.;Doi H，Kitajima K，Tanooka M，Terada T，Noguchi K，Takada Y，Fujiwara M，Ishikura R，Kamikonya N，Hirota S．
我们研究的目的是评估来自日本一家机构的晚期老年患者（年龄≥75 岁）接受放射治疗 (RT) 的可行性。我们回顾性分析了2000年至2015年期间因病理证实的鼻窦癌而接受放疗的14例患者（11例上颌窦癌患者和3例筛窦癌患者）。进行 RT 时没有意外停止。然而，两名患者出现了 3 级粘膜炎。中位随访时间为 13 个月（范围 2-54 个月）。 1 年和 2 年总生存 (OS) 率分别为 81.8 % 和 54.5%。初次治疗后的局部缓解率为 85.7%。 1 年和 2 年无进展生存 (PFS) 率分别为 46.2% 和 24.8%。对不同临床病理学参数进行单变量分析，以确定与 OS 和 PFS 的关联。我们证明，>60 Gy 的调强放射治疗 (IMRT) 联合动脉内（基于顺铂）输注放化疗可改善 OS 和 PFS 率，但未观察到统计学意义。此外，在 13 个月（范围 12-25 个月）的中位随访期内，接受 33 次 66 Gy 剂量的鳞状细胞癌 (SCC) 患者均未死亡。总之，对于晚期老年鼻窦癌患者，放疗联合动脉内（基于顺铂）输注放化疗可被认为是一种有效、耐受性良好且可行的治疗选择。此外，IMRT 中 >60 Gy 的放疗可改善老年鼻窦癌患者的生存结果。
The purpose of our study was to assess the feasibility of radiotherapy (RT) for locally advanced paranasal sinus carcinomas in late elderly patients (aged ≥75 years) from a single institution in Japan. From 2000 to 2015, we retrospectively analyzed 14 patients (11 maxillary and 3 ethmoid sinus carcinoma patients) who underwent RT for pathologically confirmed paranasal sinus carcinomas. RT was performed without unexpected cessations. Two patients, however, developed Grade 3 mucositis. The median follow-up duration was 13 months (range 2–54 months). The 1- and 2-year overall survival (OS) rates were 81.8 and 54.5 %, respectively. The local response rate after the initial treatment was 85.7 %. The 1- and 2-year progression-free survival (PFS) rates were 46.2 and 24.8 %, respectively. Univariate analysis of different clinicopathological parameters was conducted to identify associations with OS and PFS. We demonstrated that intensity modulated radiation therapy (IMRT) of >60 Gy with concomitant intra-arterial (cisplatin-based) infusion chemoradiotherapy led to improved OS and PFS rates, although no statistical significance was observed. Moreover, none of the squamous cell carcinoma (SCC) patients who received 33 fractions of 66 Gy in IMRT died during the median follow-up period of 13 months (range 12–25 months). In conclusion, RT with concomitant intra-arterial (cisplatin-based) infusion chemoradiotherapy can be considered an effective, well-tolerated, and feasible treatment option for late elderly patients with paranasal sinus carcinomas. In addition, >60 Gy of RT in IMRT led to improved survival outcomes in elderly paranasal sinus carcinoma patients.